— New drug applications for omadacycline accepted for priority review by FDA; PDUFA action date in October 2018 —
— Company on track for a first quarter 2019 omadacycline U.S. launch —
— Company strengthens balance sheet to support commercial launch —
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results and provided an update on financial, clinical, commercial and regulatory filing activities for the quarter ended March 31, 2018.
“The positive momentum we generated in 2017 continu…
READ FULL TEXT